P. Mahendra

发表

Diagnosis and management of chronic graft‐versus‐host disease

J. Scarisbrick, F. Dignan, P. Amrolia, 2012, British journal of haematology.

Gynaecomastia with hypergonadotrophic hypogonadism and Leydig cell insufficiency in recipients of high-dose chemotherapy or chemo-radiotherapy

P. Mahendra, D. Linch, R. Chatterjee, 2001, Bone Marrow Transplantation.

Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies

R. Marcus, T. Baglin, P. Mahendra, 1998, British journal of haematology.

The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia.

C. Craddock, C. Fegan, P. Moss, 2004, Blood.

Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection

C. Craddock, P. Mahendra, M. Cook, 2004, Bone Marrow Transplantation.

Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation.

R. Marcus, T. Baglin, P. Mahendra, 1995, Bone marrow transplantation.

Organ‐specific management and supportive care in chronic graft‐versus‐host disease

J. Scarisbrick, F. Fortune, F. Dignan, 2012, British journal of haematology.

BCSH/BSBMT Guideline: Diagnosis and Management of Chronic Graft- versus-Host Disease

F. Dignan, P. Amrolia, A. Clark, 2012 .

BCSH/BSBMT Guideline: Organ-Specific Management and Supportive Care in Chronic Graft-versus -Host Disease

F. Fortune, A. Clark, G. Jackson, 2012 .

Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells.

C. Craddock, P. Moss, K. Piper, 2004, Blood.

Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD 4 CD 25 high regulatory T cells

C. Craddock, P. Moss, K. Piper, 2004 .

A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study

P. Mahendra, M. Scott, H. Jestice, 1998, Bone Marrow Transplantation.

Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma

P. Mahendra, S. Tauro, M. Hastings, 2000, Bone Marrow Transplantation.

Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.

C. Craddock, D. Hochhauser, V. Spanswick, 2000, Blood.

resistance to melphalan in multiple myeloma Repair of DNA interstrand crosslinks as a mechanism of clinical

C. Craddock, V. Spanswick, J. Hartley, 2008 .

Rapid progression of 'retinoic acid syndrome' in the hypogranular variant of acute promyelocytic leukaemia, despite treatment with dexamethasone and conventional chemotherapy.

P. Mahendra, R. E. Marcus, K. Harman, 2008, Clinical and laboratory haematology.

Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial

C. Crawley, A. Hunter, G. Cook, 2009, Bone Marrow Transplantation.

patients for lymphoproliferative diseases: GVHD, toxicity and survival in 65 BEAM-Campath reduced intensity allogeneic stem cell transplantation

G. Mufti, C. Craddock, J. Byrne, 2013 .

lymphoma transplantation regimen for relapsed and refractory non-Hodgkin Outcomes after alemtuzumab-containing reduced-intensity allogeneic

C. Craddock, S. Mackinnon, K. Peggs, 2008 .

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

G. Mufti, C. Craddock, N. Russell, 2004, Blood.

Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes

J. Garcia-conde, J. Sierra, S. Mackinnon, 2007, British journal of haematology.

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

C. Craddock, S. Mackinnon, K. Peggs, 2005, The Lancet.

Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study.

A. Barrett, P. Mahendra, P. Palmer, 1990, Leukemia research.

Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

C. Craddock, P. Moss, S. Nagra, 2012, Blood.

for myeloid leukaemia following HLA-identical sibling haematopoietic stem cell transplantation The impact of donor KIR and patient HLA-C genotypes on outcome

C. Craddock, C. Fegan, P. Moss, 2013 .

CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden.

P. Moss, K. Piper, O. Goodyear, 2005, Blood.

Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.

C. Craddock, C. Fegan, P. Moss, 2005, Blood.

with disease burden many patients with multiple myeloma, and their frequency correlates CD8+T cells specific for cancer germline gene antigens are found in

K. Piper, O. Goodyear, N. Khan, 2013 .

after allogeneic stem cell transplantation Direct visualization of cytomegalovirus-specific T-cell reconstitution

C. Craddock, P. Moss, J. Ainsworth, 2012 .

Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT

C. Craddock, P. Moss, K. Piper, 2009, Bone Marrow Transplantation.

TGF beta 1 and IL-4 have opposing effects on the proliferation of chronic phase chronic myeloid leukaemic cells stimulated by G-CSF in vitro.

P. Mahendra, B. Millar, J. Treleaven, 1994, Leukemia & lymphoma.

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.

G. Morgan, S. Mackinnon, S. Verfuerth, 2001, Cytotherapy.

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

G. Mufti, C. Craddock, J. Byrne, 2001, Cytotherapy.

Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.

R. Marcus, P. Mahendra, J. Apperley, 1995, Leukemia & lymphoma.

Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.

R. Marcus, P. Mahendra, C. Wilson, 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

Measurement of reticulated platelets following peripheral blood progenitor cell and bone marrow transplantation: implications for marrow reconstitution and the use of thrombopoietin.

R. Marcus, T. Baglin, P. Mahendra, 1996, Bone marrow transplantation.

Diagnosis and management of acute graft‐versus‐host disease

J. Scarisbrick, F. Dignan, P. Amrolia, 2012, British journal of haematology.

Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia

R. Marcus, C. Craddock, P. Mahendra, 2003, Bone Marrow Transplantation.

Donor KIR Genotype Does Not Affect VZV Reactivation after Allogeneic Haematopoietic Stem Cell Transplantation.

C. Craddock, P. Moss, S. Nagra, 2005 .

The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study

C. Fegan, J. Byrne, J. Snowden, 2006, British journal of haematology.

Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia.

C. Craddock, S. Mackinnon, K. Peggs, 2001 .

Dose‐intensified treatment of Burkitt lymphoma and B‐cell lymphoma unclassifiable, (with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma) in young adults (<50 years): A comparison of two adapted BFM protocols

J. Delabie, H. Holte, P. Mahendra, 2010, American journal of hematology.

A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.

S. Mackinnon, H. Waldmann, D. Linch, 1999 .

transplantation cytomegalovirus reactivation following T-cell replete stem cell genotype has a major influence on the rate of KIR Donor

C. Craddock, C. Fegan, P. Moss, 2012 .

Successful use of Campath-1H in the treatment of steroid refractory liver GvHD

C. Craddock, P. Mahendra, M. Cook, 2004, Bone Marrow Transplantation.

CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect

C. Craddock, P. Moss, K. Piper, 2010, Haematologica.

Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning – evidence for a superior outcome using melphalan combined with total body irradiation

N. Russell, J. Cavenagh, P. Mahendra, 2005, British journal of haematology.

CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation.

C. Craddock, P. Moss, K. Piper, 2007, Blood.

High-hyperdiploidy in Philadelphia positive adult acute lymphoblastic leukaemia: case-series and review of literature

C. Craddock, P. Mahendra, S. Tauro, 2003, Bone Marrow Transplantation.

Two unusual neurological presentations of granulocytic sarcoma in Philadelphia positive chronic myeloid leukaemia.

A. Green, R. Marcus, P. Mahendra, 1994, Leukemia & lymphoma.

Hodgkin's disease after cardiac transplant: a report of two cases.

P. Mahendra, R. E. Marcus, I. Hood, 1996, Clinical and laboratory haematology.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

G. Morgan, S. Mackinnon, K. Peggs, 2000, Blood.

SEVERE HEMOSIDEROSIS POST ALLOGENEIC BONE MARROW TRANSPLANTATION

P. Mahendra, G. Bass, R. Marcus, 1996, Hematological oncology.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

C. Craddock, S. Mackinnon, K. Peggs, 2002, Blood.

Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease1

C. Craddock, P. Moss, P. Mahendra, 2003, Transplantation.

Short-course intravenous antibiotics with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or peripheral blood progenitor cell transplant recipients.

R. Marcus, T. Baglin, P. Mahendra, 1996, Acta haematologica.

Chloroma (aleukaemic leukaemia cutis) initially diagnosed as cutaneous lymphoma

P. Mahendra, E. Jones, J. Marsden, 2002, Clinical and experimental dermatology.

Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin.

T. Baglin, P. Mahendra, D. Keeling, 2010, Clinical and laboratory haematology.

Burkitt's lymphoma: single-centre experience with modified BFM protocol.

L. Jones, P. Mahendra, S. Paneesha, 2002, Clinical and laboratory haematology.

Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure

P. Mahendra, G. Lipkin, S. Tauro, 2002, Bone Marrow Transplantation.

Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation

C. Craddock, A. Ho, P. Mahendra, 2005, Bone Marrow Transplantation.

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.

C. Craddock, P. Moss, J. Ainsworth, 2001, Blood.

reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem

C. Fegan, S. Mackinnon, K. Peggs, 2008 .

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

C. Craddock, C. Fegan, S. Mackinnon, 2002, Blood.

Late onset immune pancytopenia following bone marrow transplantation

M. McMullin, P. Mahendra, L. Tyfield, 1991, British journal of haematology.

Myelodysplasia as the initial presentation of Fanconi's anaemia in a phenotypically normal child.

A. Barrett, M. McMullin, P. Mahendra, 2008, Clinical and laboratory haematology.

Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.

C. Craddock, P. Moss, S. Nagra, 2013, Leukemia research.

CXCL 10-CXCR 3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation

C. Craddock, P. Moss, K. Piper, 2007 .

Thrombocytopenia and spontaneous rupture of the spleen associated with infectious mononucleosis.

P. Mahendra, J. R. MacGowan, R. E. Marcus, 2008, Clinical and laboratory haematology.

The use of non-cryopreserved peripheral blood progenitor cells in autologous transplantation.

R. Marcus, P. Mahendra, S. Ager, 1995, Bone marrow transplantation.

nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following

G. Morgan, S. Mackinnon, K. Peggs, 2013 .

Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition

P. van Endert, S. Tenzer, H. Schild, 2009, Proceedings of the National Academy of Sciences.

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

C. Craddock, N. Russell, S. Mackinnon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

C. Craddock, S. Mackinnon, K. Peggs, 2004, Blood.

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers

C. Craddock, P. Moss, L. Billingham, 2005, The Journal of experimental medicine.

High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.

T. Baglin, P. Mahendra, S. Ager, 1996, Bone marrow transplantation.

Peripheral blood stem cell transplantation for POEMS syndrome

M. Reilly, P. Mahendra, K. Yong, 2002, Bone Marrow Transplantation.

Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis

J. Ward, R. Malladi, P. Mahendra, 2013, Bone Marrow Transplantation.

High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.

R. Marcus, T. Baglin, P. Mahendra, 1996, Bone marrow transplantation.

Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.

R. Marcus, T. Baglin, P. Mahendra, 1996, Bone marrow transplantation.

Technetium (99mTc)-labelled white cell scanning, 51Cr-EDTA and 14C-mannitol-labelled intestinal permeability studies: non-invasive methods of diagnosing acute intestinal graft-versus-host disease.

R. Marcus, P. Mahendra, P. Ancliff, 1994, Bone Marrow Transplantation.

Rare cancers of the head and neck

R. Grimer, P. Mahendra, A. Hartley, 2012 .

Resolution of sarcoidosis after allogeneic bone marrow transplantation with donor lymphocyte infusions

P. Mahendra, S. Tauro, 2001, Bone Marrow Transplantation.

Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect.

C. Craddock, S. Mackinnon, A. Hunter, 2001 .

Quinolone resistance in neutropenic patients: the effect of prescribing policy in the UK and Pakistan.

P. Mahendra, M. Hastings, R. Hassan, 2001, Clinical and laboratory haematology.

Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation

C. Craddock, P. Mahendra, S. Lawson, 2006, Bone Marrow Transplantation.

An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma.

J. Mehta, P. Mahendra, R. Powles, 1993, Leukemia & lymphoma.

Transplant Donor KIR Genotype Influences the Rate of CMV Reactivation Following T-Replete Stem Cell Transplantation.

C. Craddock, C. Fegan, P. Moss, 2004 .

Autografting for multiple myeloma: a 5-year experience at a single institution.

R. Marcus, T. Baglin, P. Mahendra, 1995, Bone marrow transplantation.

Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions.

P. Mahendra, F. Wandroo, J. Neilson, 2005, Clinical and laboratory haematology.

Increased risk for myelodysplastic syndrome in individuals with glutathione transferase theta 1 gene (GSTT1) defect

P. Mahendra, 1996 .

SEVERE HEMOSIDEROSIS POST ALLOGENEIC BONE MARROW TRANSPLANTATION

R. Marcus, P. Mahendra, G. Bass, 1996, Hematological oncology.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

J. Leonard, B. Cheson, H. Holte, 2006 .

t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.

P. Mahendra, P. Sinclair, E. Nacheva, 1996, Clinical and laboratory haematology.

Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect.

C. Craddock, S. Mackinnon, A. Hunter, 2003 .

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

C. Craddock, S. Mackinnon, K. Peggs, 2002, Blood.